SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively[1].

S116836 is a tyrosine kinase inhibitor.

BCR-ABL1-IN-1 is a highly potent and orally bioavailable inhibitor, displaying remarkable specificity towards ABL kinase. Notably, this compound holds significant promise for delineating the precise involvement of ABL kinases within the central nervous system, particularly in preclinical investigations [1].

ADH-1 (Exherin) 是N-cadherin 的拮抗剂，对 N-cadherin 介导的细胞黏附具有抑制作用。

INS018 055 (TNIK&MAP4K4-IN-2) 是一种高效性的 TNIK 和 MAP4K4 抑制剂，具有抗纤维化活性，可用于研究特发性肺纤维化。

ADH-1 trifluoroacetate (Exherin trifluoroacetate) 是一种选择性的、竞争性N-钙粘蛋白拮抗剂，具有潜在抗肿瘤和抗血管生成作用。

HDAC-IN-55(8j)是一种小分子化合物，能够上调E-钙粘蛋白的表达并抑制癌细胞的增殖。

SLEC-11 可在E-钙粘蛋白缺陷细胞中作为合成致死(SL)的先导化合物出现，具有治疗胃癌的潜力。

BAS00093476是一种有效的E-cadherin抑制剂，能够在人胰腺肿瘤BxPC-3细胞中抑制E-cadherin介导的细胞-细胞黏附，可用于研究相关肿瘤。